Pemetrexed therapy in elderly patients with good performance status: Analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer

Clinical Lung Cancer

Volumn 13, Issue 5, 2012, Pages 340-346

  Gridelli, Cesare ^a   Brodowicz, Thomas ^b,c   Langer, Corey J ^d   Peterson, Patrick ^e   Islam, Mominul ^f   Guba, Susan C ^e   Moore, Patti ^e   Visseren Grul, Carla M ^e   Scagliotti, Giorgio ^g  

^a S G MOSCATI HOSPITAL   (Italy)

^b Central European Cooperative Oncology Group Austria   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f Global I3   (United States)

^g UNIVERSITY OF TURIN   (Italy)

Author keywords

Elderly; Non Small cell lung cancer; Nonsquamous histology; Pemetrexed

Indexed keywords

CISPLATIN; GEMCITABINE; PEMETREXED; PLACEBO;

ABDOMINAL DISTENSION; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOATING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DICHOTIC LISTENING; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GOOD PERFORMANCE STATUS SCORE; HAZARD RATIO; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84865450666     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.12.002     Document Type: Article

References (36)

1. P.A. Bunn Jr, R. Lilenbaum Chemotherapy for elderly patients with advanced non-small-cell lung cancer J Natl Cancer Inst 95 2003 341 343
2. A.G. Pallis, C. Gridelli, J.P. van Meerbeeck EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population Ann Oncol 21 2010 692 706
3. S.D. Ramsey, N. Howlader, R.D. Etzioni Chemotherapy use, outcomes, and costs for older persons with advanced Non-Small-cell lung cancer: evidence from surveillance, epidemiology and end resultsmedicare J Clin Oncol 22 2004 4971 4978
4. T. Asmis, K. Ding, L. Seymour Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer; a review of National Cancer Institute of Canada Clinical Trials Group trials J Clin Oncol 26 2008 54 59
5. C.J. Langer, J. Manola, P. Bernardo Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial J Natl Cancer Inst 94 2002 173 181
6. K. Kelly, J. Crowley, P.A. Bunn Jr Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
7. G.V. Scagliotti, P. Parikh, J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
8. T. Ciuleanu, T. Brodowicz, C. Zielinski Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
9. L.E. Coate, C. Massey, A. Hope Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer J Thorac Oncol 6 2011 537 544
10. A.J. Davidoff, M. Tang, B. Seal Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer J Clin Oncol 28 2010 2191 2197
11. C. Gridelli Treatment of advanced non-small-cell lung cancer: from best supportive care to the combination of platin-based chemotherapy and targeted therapies J Clin Oncol 26 2008 13 15
12. C.G. Azzoli, S. Baker Jr, S. Temin American Society of Clinical Oncology American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 2009 6251 6266
13. ALIMTA® (pemetrexed for injection) [package insert] July 2009 Eli Lilly and Company Indianapolis, IN
14. United States Food and Drug Administration Guideline for industry Studies in support of special populations: geriatrics. ICH-E7 http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073131.pdf Accessed: August 24, 2011
15. Committee for Human Medicinal Products (CHMP) Adequacy of guidance on the elderly regarding medicinal products for human use http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2010/01/WC500049541.pdf Accessed: August 17, 2011
16. D.S. Ettinger, W. Akerley, G. Bepler NCCN Non-Small Cell Lung Cancer Panel Members Non-small cell lung cancer J Natl Compr Canc Netw 8 2010 740 801
17. J.M. Trigo Prez, P. Garrido Lpez, E. Felip Font SEOM (Spanish Society for Medical Oncology) SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition Clin Transl Oncol 12 2010 735 741
18. G. D'Addario, M. Frh, M. Reck ESMO Guidelines Working Group Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 suppl 5 2010 v116 v119
19. G. Scagliotti, T. Brodowicz, F.A. Shepherd Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer J Thorac Oncol 6 2011 64 70
20. S.G. Arbuck, S.P. Ivy, A. Setser Cancer Therapy Evaluation Program Common Toxicity Criteria (CTC), Version 2.0 Published on April 30, 1999 http://www.eortc.be/services/doc/ctc/ctcv20-4-30-992.pdf Accessed: August 17, 2011
21. National Cancer Institute Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 Published August 9, 2006 http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf Accessed: August 17, 2011
22. E.A. Quoix, G. Zalcman, J. Oster Intergroupe Francophone de Cancrologie Thoracique Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial Lancet 378 2011 1079 1088
23. M. Reck, J. Von Pawel, J.R. Fischer German Thoracic Oncology Working Group Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): a randomized phase II study of the German Thoracic Oncology Working Group J Clin Oncol 28 suppl 2010 15 abstract 7565 www.asco.org Accessed: December 19, 2011
24. C.M. Rocha Lima, J.E. Herndon 2nd, M. Kosty Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B Cancer 94 2002 181 187
25. S.E. Schild, P.J. Stella, S.M. Geyer The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly J Clin Oncol 21 2003 3201 3206
26. L.V. Sequist, T.J. Lynch Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes! J Clin Oncol 21 2003 3186 3188
27. C. Gridelli The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer Elderly Lung Cancer Vinorelbine Italian Study Oncologist 6 suppl 1 2001 4 7
28. C. Gridelli, F. Perrone, C. Gallo MILES Investigators Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362 372
29. F.V. Fossella, C.P. Belani TAX 326 Study Group Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC): Analyses in elderly patients Proc Am Soc Clin Oncol 22 2003 abstract 2528 www.asco.org Accessed: December 19, 2011
30. K. Kelly, S. Giarritta, W. Akerley Should older patients (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308 Proc Am Soc Clin Oncol 20 2001 abstract 1313 www.asco.org Accessed: December 19, 2011
31. C.J. Langer, M. Vangel, J. Schiller Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 yrs) with NSCLC do as well as younger pts (<70) Proc Am Soc Clin Oncol 22 2003 abstract 2571 www.asco.org Accessed: December 19, 2011
32. P.M. Kulkarni, R. Chen, T. Anand Efficacy and safety of pemetrexed cancer patients: results of an integrated analysis Crit Rev Oncol Hematol 67 2008 64 70
33. O. Altundag, D.J. Stewart, F.V. Fossella Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy J Thorac Oncol 2 2007 141 146
34. P.J. Hesketh, R.C. Lilenbaum, K. Chansky Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6 J Thorac Oncol 2 2007 494 498
35. G. Des Guetz, B. Uzzan, P. Nicolas Comparison of efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis J Clin Oncol 28 suppl 2010 15 abstract 7625 www.asco.org Accessed: December 19, 2011
36. G.J. Weiss, C. Langer, R. Rosell Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 24 2006 4405 4411